Nuclear Medicine Market to Reach US$ 57.3 Billion by 2035, Driven by Rising Cancer Burden, Theranostics, and Advances in Radiopharmaceuticals

The global nuclear medicine market was valued at US$ 18.6 billion in 2024 and is projected to reach US$ 57.3 billion by 2035, expanding at a CAGR of 10.8% from 2025 to 2035. The market is expected to witness significant growth driven by increasing adoption of nuclear medicine for diagnostic imaging and targeted therapeutic applications, rising prevalence of chronic diseases and cancer, and continued advancements in radiopharmaceuticals and imaging technologies.

Nuclear medicine uses radioactive substances for diagnostic imaging and targeted treatment of diseases. Growing investments in radiopharmaceutical production, improved imaging technologies, and the development of targeted radionuclide therapies are creating significant opportunities for market participants.

Review significant findings and insights from our Report in this sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4672

Market Overview

Nuclear medicine implies a medical imaging subspecialty that uses radiopharmaceuticals or radioactive medications to diagnose and treat disease. It is one of the valuable resources for the early diagnosis of diseases such as cardiovascular disease, cancer, and neurological disorders.

Nuclear medicine lets physicians to visualize the way tissues and organs are functioning by introducing small quantities of radioactive material into the body, thereby providing information not found using the other forms of standard imaging.

These tests are non-painful and may be performed by single photon emission computed tomography (SPECT) and positron emission tomography (PET). Apart from diagnosis, nuclear medicine is also delivered as targeted radionuclide therapy, with the potential to target cancer cells for selective destruction.

Key Market Growth Drivers

Rising Prevalence of Cancer

The growing global burden of cancer is increasing demand for advanced diagnostic imaging and targeted treatment approaches.

PET and SPECT imaging are increasingly used for disease detection, staging, treatment planning, and monitoring, while targeted radionuclide therapies are gaining traction in oncology.

Growing Adoption of Theranostics

Theranostics combines diagnostic imaging with targeted radionuclide therapy to enable more personalized treatment strategies.

The growing availability of radioligand therapies and other targeted approaches is creating new opportunities for nuclear medicine providers and radiopharmaceutical manufacturers.

Advances in Radiopharmaceuticals

Continuous development of new radioisotopes and radiopharmaceutical formulations is expanding the range of diagnostic and therapeutic applications.

Improved isotope production, radiochemistry, and targeted delivery technologies are supporting the development of next-generation nuclear medicine solutions.

Increasing Demand for Molecular Imaging

Healthcare providers are increasingly adopting imaging technologies that provide functional and molecular information rather than relying solely on anatomical imaging.

Nuclear medicine technologies can help clinicians identify disease processes and evaluate treatment response, supporting their adoption in oncology, cardiology, neurology, and other specialties.

Analysis of Key Players

The nuclear medicine market is competitive, with pharmaceutical companies, radiopharmaceutical manufacturers, medical imaging companies, and specialized healthcare technology providers focusing on diagnostic and therapeutic solutions.

• Cardinal Health
• Jubilant Pharma Company
• The Bracco Group
• Nordion (Canada) Inc.
• NTP Radioisotopes SOC Ltd.
• ECZACIBAŞI-MONROL
• Lantheus
• China lsotope & Radiation Corporation
• Eckert & Ziegler Medical
• Mallinckrodt plc
• GE HealthCare
• Blue Earth Diagnostics
• NorthStar Medical Radioisotopes, LLC
• B. J. Madan & Co
• Curium Pharma
• Novartis AG
• Bayer AG
• Other prominent players

Market participants are focusing on radiopharmaceutical development, isotope production, targeted radionuclide therapies, molecular imaging systems, and expansion of radiopharmaceutical manufacturing capacity.

Key Player Strategies

Leading companies are implementing several strategic initiatives to strengthen their market positions:

• Development of novel radiopharmaceuticals
• Expansion of targeted radionuclide therapy portfolios
• Investment in radioisotope production capacity
• Development of advanced PET and SPECT imaging systems
• Strategic partnerships and licensing agreements
• Mergers and acquisitions
• Expansion of radiopharmaceutical manufacturing facilities
• Development of theranostic platforms
• Investment in molecular imaging technologies
• Expansion of distribution networks

These strategies are helping companies respond to increasing demand for personalized diagnostics and targeted cancer therapies.

Market Challenges & Opportunities

Challenges

The market faces challenges including the short half-life of certain radioisotopes, complex supply-chain requirements, limited availability of specialized infrastructure, high equipment and operational costs, and regulatory complexities.

The requirement for specialized personnel and strict radiation safety protocols can also create barriers to adoption, particularly in emerging markets.

Opportunities

The expansion of targeted radionuclide therapy and theranostics presents significant opportunities for market participants.

Growing investments in isotope production, radiopharmaceutical manufacturing, PET and SPECT infrastructure, and personalized medicine are expected to create additional growth opportunities.

Emerging applications in oncology, neurology, cardiology, and other therapeutic areas can further expand the addressable market.

Investment Landscape and ROI Outlook

The Nuclear Medicine Market continues to attract investments from pharmaceutical companies, radiopharmaceutical developers, healthcare technology companies, hospitals, research institutions, and specialized manufacturers.

Investment is increasingly directed toward radioisotope production, radiopharmaceutical manufacturing, targeted therapies, molecular imaging, and theranostic platforms.

With the market projected to increase from US$ 18.6 Billion in 2024 to US$ 57.3 Billion by 2035, the industry presents substantial long-term commercial opportunities. The projected 10.8% CAGR reflects strong demand for advanced diagnostic and therapeutic nuclear medicine solutions.

Market Segmentation

Product Type

• Diagnostics Products
• SPECT
• Technetium-99m (TC-99m)
• Thallium-201 (Tl-201)
• Gallium-67 (GA-67)
• Iodine-123 (I-123)
• Others (Indium-111, etc.)
• PET
• Fluorine-18 (F-18)
• Rubidium-82 (Rb-82)/Strontium-82 (Sr-82)
• Nitrogen-13 (N-13)
• Others (C-11 (Carbon-11), etc.)
• Others (In-vitro Diagnostic kit, etc.)
• Therapeutic Products
• Alpha Emitters
• Radium-223 (RA-223)
• Others (Bismuth-213 (Bi-213), etc.)
• Beta Emitters
• Iodine-131 (I-131)
• Sodium Phosphate [32P]
• Yttrium-90 (Y-90)
• Samarium-153 (SM-153)
• Rhenium 186 (Re-186)
• Lutetium-177 (Lu-117)
• Others (Holmium-166 (Ho-166), etc.)
• Brachytherapy
• Cesium-131 (Cs-131)
• Iodine-125 (I-125)
• Palladium-103 (Pd-103)
• Iridium-192 (Ir-192)

Application

• Cardiology
• Neurology
• Oncology
• Thyroid
• Lymphoma
• Bone Metastasis
• Endocrine Tumor
• Others (Autoimmune disease, etc.)

End-user

• Hospitals and Clinics
• Diagnostic Centers
• Others (Research Laboratories, etc.)

Why Buy This Report?

• Gain comprehensive insights into current and future nuclear medicine market trends
• Access detailed market size estimates and forecasts through 2035
• Understand key growth drivers, challenges, and emerging opportunities
• Evaluate competitive positioning of leading nuclear medicine companies
• Analyze demand for diagnostic and therapeutic radiopharmaceuticals
• Assess the impact of theranostics and targeted radionuclide therapy
• Analyze regional and segment-level market dynamics
• Identify high-growth investment opportunities
• Track product launches, partnerships, acquisitions, and manufacturing expansions
• Evaluate opportunities arising from molecular imaging and personalized medicine
• Understand emerging applications across oncology, cardiology, and neurology
• Support strategic business planning and investment decisions

Buy this Premium Research Report to gain valuable industry intelligence - https://www.transparencymarketresearch.com/checkout.php?rep_id=4672<ype=S

Frequently Asked Questions

·        How big was the global nuclear medicine market in 2024?

It was valued at US$ 18.6 Bn in 2024

·        What is the projected size of the nuclear medicine market by 2035?

It is projected to cross US$ 57.3 Bn by the end of 2035

·        What are the factors driving the nuclear medicine market?

Growing adoption of hybrid imaging systems and increased demand for early and accurate diagnosis

·        What is the nuclear medicine industry expected to grow during the forecast period?

It is anticipated to grow at a CAGR of 10.8% from 2025 to 2035

·        Which region is expected to dominate the nuclear medicine market during the forecast period?

North America is expected to account for the largest share from 2025 to 2035

Explore Latest Research Reports by Transparency Market Research:

Anal Fistula Treatment Market

Metastatic Bone Disease Market

Human Papillomavirus Vaccine Market

Sterilization Wrap Market

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite 700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com  

Sales Inquiries: sales@transparencymarketresearch.com  

Media Inquiries: media@transparencymarketresearch.com